Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Nivolumab (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 23 Feb 2017 Planned End Date changed from 1 Sep 2021 to 1 Jun 2021.
- 06 Dec 2016 Results (n=12) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 24 Oct 2016 Planned number of patients changed from 48 to 72.